A Metabolic-associated Nomogram Predicts Recurrence Survival of Thyroid Cancer

Abstract

Objective

Various studies have suggested that metabolic genes play a significant role in papillary thyroid cancer (PTC). The current study aimed to identify a metabolic signature related biomarker to predict the prognosis of patients with PTC.

Methods

We conducted a comprehensive analysis on the data obtained from the Cancer Genome Atlas (TCGA) database. The correlation between survival result and metabolic genes was evaluated based on the univariate Cox analyses, least absolute shrinkage and selection operator (LASSO) and multivariate Cox analyses. The performance of a 7-gene signature was assessed according to Kaplan-Meier and receiver operating characteristic (ROC) analysis. Multivariate Cox regression analysis was adopted to unearth clinical factors related to the recurrence free survival (RFS) of patients with PTC. Finally, a prognostic nomogram was developed based on risk score, cancer status and cancer width to improve the prediction for RFS of PTC patients.

Results

Seven metabolic genes were used to establish the prognostic model. The ROC curve and C-index exhibited high value in training, testing and the whole TCGA datasets. The established nomogram, incorporating the 7-metabolic gene signature and clinical factors, was able to predict the RFS with high effectiveness. The 7-metabolic gene signature-based nomogram had a good performance to predict the RFS of patients with PTC.

Conclusion

Our study identified a 7-metabolic gene signature and established a prognostic nomogram, which were useful in predicting the RFS of PTC.

Keywords

signature / metabolism / papillary thyroid cancer / recurrence free survival / nomogram

References

[1] WangJ, YuF, ShangY, et al.. Thyroid cancer: incidence and mortality trends in China, 2005–2015. Endocrine, 2020, 68(1): 163-173

[2] PowersAE, MarcadisAR, LeeM, et al.. Changes in Trends in Thyroid Cancer Incidence in the United States, 1992 to 2016. JAMA, 2019, 322(24): 2440-2441

[3] JamesBC, MitchellJM, JeonHD, et al.. An update in international trends in incidence rates of thyroid cancer, 1973–2007. Cancer Causes Control, 2018, 29(4–5): 465-473

[4] SiołekM, CybulskiC, Gąsior-PerczakD, et al.. CHEK2 mutations and the risk of papillary thyroid cancer. Int J Cancer, 2015, 137(3): 548-552

[5] BerdelouA, LamartinaL, KlainM, et al.. Treatment of refractory thyroid cancer. Endocr Relat Cancer, 2018, 25(4): R209-r223

[6] PavlovaNN, ThompsonCB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab, 2016, 23(1): 27-47

[7] LinX, XuR, MaoS, et al.. Metabolic biomarker signature for predicting the effect of neoadjuvant chemotherapy of breast cancer. Ann Transl Med, 2019, 7(22): 670

[8] RenJ, FengJ, SongW, et al.. Development and validation of a metabolic gene signature for predicting overall survival in patients with colon cancer. Clin Exp Med, 2020, 20(4): 535-544

[9] LiuY, WangL, LiuH, et al.. The Prognostic Significance of Metabolic Syndrome and a Related Six-lncRNA Signature in Esophageal Squamous Cell Carcinoma. Front Oncol, 2020, 10: 61

[10] YuX, ZhangX, ZhangY. Identification of a 5-Gene Metabolic Signature for Predicting Prognosis Based on an Integrated Analysis of Tumor Microenvironment in Lung Adenocarcinoma. J Oncol, 2020, 2020: 5310793

[11] ChenJ, YeC, DongJ, et al.. Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer. J Transl Med, 2020, 18(1): 59

[12] WangC, GuoW, ZhouM, et al.. The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. Clin Cancer Res, 2016, 22(7): 1603-1610

[13] ColapricoA, SilvaTC, OlsenC, et al.. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res, 2016, 44(8): e71

[14] PossematoR, MarksKM, ShaulYD, et al.. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature, 2011, 476(7360): 346-350

[15] Harrell FE Jr. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis (2nd Edition). Springer, 2015.

[16] CabanillasME, McFaddenDG, DuranteC. Thyroid cancer. Lancet, 2016, 388(10061): 2783-2795

[17] HaugenBR, AlexanderEK, BibleKC, et al.. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26(1): 1-133

[18] RenP, ZhangJG, XiuL, et al.. Clinical significance of phospholipase A2 group IIA (PLA2G2A) expression in primary resected esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci, 2013, 17(6): 752-757

[19] DuJ, ZhouY, LiY, et al.. Identification of Frataxin as a regulator of ferroptosis. Redox Biol, 2020, 32: 101483

[20] LiuK, ZhengM, LuR, et al.. The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review. Cancer Cell Int, 2020, 20: 213

[21] SunY, LongH, SunL, et al.. PGM5 is a promising biomarker and may predict the prognosis of colorectal cancer patients. Cancer Cell Int, 2019, 19: 253

[22] FengL, SunP, LiZ, et al.. Knockdown of PPP5C inhibits growth of hepatocellular carcinoma cells in vitro. Appl Biochem Biotechnol, 2015, 175(1): 526-534

[23] XuB, HuangC, YangX, et al.. Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancer. Oncol Lett, 2018, 15(4): 5185-5192

[24] ZhuZ, YuZ, RongZ, et al.. The novel GINS4 axis promotes gastric cancer growth and progression by activating Rac1 and CDC42. Theranostics, 2019, 9(26): 8294-8311